Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics (NASDAQ:TNYA) will report new interim data from Cohorts 1 and 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.

Rhea-AI Summary

Tenaya Therapeutics (NASDAQ:TNYA) will report new interim data from Cohorts 1 and 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.

Management will host a webcast at 8:00 a.m. ET, accessible via the Investors section under “Events & Presentations,” with an archived replay available for about 30 days.

Argus Jun 3 session

-0.53% close to close Open Argus

Details

News Market Reaction – TNYA

On Jun 3, the first trading day after this news, TNYA closed 0.53% below the previous close.

Data tracked by StockTitan Argus for the Jun 3 session.

Market Context

This announcement schedules new interim data from the MyPEAK-1 Phase 1b/2 trial of TN-201 for MYBPC3...

Analysis

This announcement schedules new interim data from the MyPEAK-1 Phase 1b/2 trial of TN-201 for MYBPC3-associated HCM, with a webcast on June 3, 2026 at 8:00 a.m. ET. Recent history includes positive earnings updates, clinical progress for TN-401, and an equity incentive plan amendment. Together, these events frame TN-201 as another important program within an active pipeline. Observers may focus on safety and efficacy details from both cohorts and how they complement earlier TN-201 and TN-401 readouts.

Key Figures

Cohorts reported: Cohort 1 and Cohort 2 Trial phase: Phase 1b/2 Webcast time: 8:00 a.m. ET +3 more

Cohorts reported

Cohort 1 and Cohort 2

Interim TN-201 data in MyPEAK-1 trial

Trial phase

Phase 1b/2

MyPEAK-1 trial design

Webcast time

8:00 a.m. ET

Scheduled data review on June 3, 2026

Webcast replay period

approximately 30 days

Archived replay availability on Tenaya website

Announcement date

June 2, 2026

Press release publication date

Data announcement date

June 3, 2026

Scheduled release of new TN-201 interim data

Historical Context

5 past events · Latest: May 29

5 events

1. May 29

   Conference participation

   24h Move

   +8.8%

   Announcement of participation and webcast access for Jefferies healthcare conference.

2. May 15

   Clinical data update

   24h Move

   -8.3%

   Positive interim TN-401 data showing reduced arrhythmia burden and EMA PRIME status.

3. May 06

   Earnings and pipeline

   24h Move

   +7.4%

   Q1 2026 results, cash runway into 2H 2027, and upcoming TN-201/TN-401 readouts.

4. Apr 27

   Clinical presentation

   24h Move

   +4.1%

   ASGCT late-breaking TN-401 data presentation and planned company webcast review.

5. Mar 11

   Earnings and funding

   24h Move

   +4.0%

   Q4/FY 2025 results, TN-201/TN-401 early readouts, and December equity raise proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1b/2, gene therapy, hypertrophic cardiomyopathy

3 terms

phase 1b/2 medical

"MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults..."

Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.

gene therapy medical

"trial of TN-201 gene therapy for adults with MYBPC3-associated..."

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

hypertrophic cardiomyopathy medical

"for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM)..."

Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.

Webcast Details:

Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1 on Wednesday, June 3, 2026 at 8:00 a.m. ET. To access the live event, participants may register here. The live webcast will be available under “Events & Presentations” in the Investors section of Tenaya’s website.

An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the live event.

About MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)
Variants in the Myosin Binding Protein C3 (MYBPC3) gene are the most common genetic cause of hypertrophic cardiomyopathy (HCM), accounting for approximately 20% of the overall HCM population, or 120,000 patients, in the United States alone. MYBPC3-associated HCM is a severe and progressive condition affecting adults, teens, children and infants. Mutations of the MYBPC3 gene result in insufficient expression of a protein, called MyBP-C, needed to regulate heart contraction. The heart becomes hypercontractile and the left ventricle thickens, resulting in symptoms such as chest pain, shortness of breath, palpitations and fainting. Patients whose disease is caused by MYBPC3 mutations are more likely than those with non-genetic forms of HCM to experience earlier disease onset and have high rates of serious outcomes, including heart failure symptoms, arrhythmias, stroke and sudden cardiac arrest or death. There are currently no approved therapeutics that address the underlying genetic cause of HCM.

About TN-201
TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to address the underlying cause of MYBPC3-associated hypertrophic cardiomyopathy (HCM) by delivering a working MYBPC3 gene to heart muscle cells via a single intravenous infusion and thereby increasing insufficient MyBP-C protein levels with the aim of halting or even reversing disease after a single dose. The U.S. Food and Drug Administration has granted TN-201 Fast Track, Orphan Drug and Rare Pediatric Drug Designations. TN-201 has also received orphan medicinal product from the European Commission.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What interim data will Tenaya Therapeutics (NASDAQ:TNYA) present from the MyPEAK-1 trial on June 3, 2026?

Tenaya Therapeutics will present new interim data from Cohorts 1 and 2 of the MyPEAK-1 Phase 1b/2 trial of TN-201 in adults with MYBPC3-associated hypertrophic cardiomyopathy. According to Tenaya, these data will be discussed during a dedicated webcast.

When is Tenaya Therapeutics’ MyPEAK-1 TN-201 data webcast scheduled on June 3, 2026?

The MyPEAK-1 TN-201 interim data webcast is scheduled for Wednesday, June 3, 2026, at 8:00 a.m. ET. According to Tenaya, investors can access the live event via registration through the Investors section of the company’s website.

How can investors access the Tenaya Therapeutics (TNYA) MyPEAK-1 interim data webcast?

Investors can access the Tenaya Therapeutics MyPEAK-1 interim data webcast by registering through a provided link in the Investors section under “Events & Presentations.” According to Tenaya, the live webcast will be streamed directly from the company’s website.

Will a replay of Tenaya Therapeutics’ June 3, 2026 MyPEAK-1 data webcast be available?

Yes, a replay of the June 3, 2026 MyPEAK-1 data webcast will be available. According to Tenaya, an archived version will remain accessible on the company’s website for approximately 30 days following the live presentation.

What is TN-201 in Tenaya Therapeutics’ MyPEAK-1 Phase 1b/2 trial for MYBPC3-associated HCM?

TN-201 is a gene therapy being evaluated in the MyPEAK-1 Phase 1b/2 trial for adults with MYBPC3-associated hypertrophic cardiomyopathy. According to Tenaya, new interim data from this ongoing study will be reported during the June 3, 2026 webcast.

What patient groups are included in Cohorts 1 and 2 of Tenaya’s MyPEAK-1 trial of TN-201?

Cohorts 1 and 2 of the MyPEAK-1 Phase 1b/2 trial involve adults with MYBPC3-associated hypertrophic cardiomyopathy receiving TN-201 gene therapy. According to Tenaya, new interim results from these two cohorts will be shared on June 3, 2026.